Sign In
Buy ANNX
$5.39
+0.130 (+2.47%)
At Close: Jun 03, 2026
Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
04:05pm, Monday, 10'th Nov 2025
Late-Stage Neuroinflammation Platform Advancing Global Registrational Programs in Guillain-Barré Syndrome ( GBS) and Geographic Atrophy (GA) Current Tanruprubart GBS Dossier On Track for MAA Filing
Annexon, Inc. (ANNX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
09:58pm, Sunday, 07'th Sep 2025
Annexon, Inc. (NASDAQ:ANNX ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 3:00 PM EDT Company Participants Douglas Love - CEO, President & Director Conference Call Participants
Annexon, Inc. (ANNX) Presents at Cantor Global Healthcare Conference 2025 Transcript
01:38am, Friday, 05'th Sep 2025
Annexon, Inc. (NASDAQ:ANNX ) Cantor Global Healthcare Conference 2025 September 4, 2025 8:00 AM EDT Company Participants Douglas Love - CEO, President & Director Conference Call Participants Pete Stav
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 18'th Aug 2025
BRISBANE, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devast
Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
04:05pm, Thursday, 14'th Aug 2025
Tanruprubart (formerly ANX005) for GBS Advancing Through Regulatory Interactions; MAA Submission in Europe Anticipated in First Quarter of 2026; Ongoing Discussions with FDA Regarding Generalizability
New Pilot Appoints Designated Product Development Coordinator to Navigate Regulatory Interactions, Respond to Ad-hoc Queries, and Support Evidence Planning
Expedited Enrollment Surpassing 630 Targeted Participants Underscores the Strong Demand for a Therapy Focused on Vision Preservation
New Strong Sell Stocks for July 22nd
07:21am, Tuesday, 22'nd Jul 2025
BLTE, DDD and ANNX have been added to the Zacks Rank #5 (Strong Sell) List on July 22, 2025.
Annexon: Lead GBS Therapy Stokes Near-Term Potential
12:47pm, Monday, 14'th Jul 2025
Annexon is a speculative Buy due to its late-stage Tanruprubart program targeting the high unmet need in Guillain-Barré Syndrome. Tanruprubart could become the standard of care for GBS if approved, g
Dr. Clark Brings 25 Years of Experience Treating Retina Diseases and Developing Emerging Therapies as a Principal Investigator in Over 70 Clinical Trials and as an Early Pioneer of VEGF Inhibitors
Annexon Biosciences to Present at the Jefferies Global Healthcare Conference
04:05pm, Thursday, 29'th May 2025
BRISBANE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastat
First Oral Presentation of the Tanruprubart Real-World Evidence (RWE) Study by International Guillain-Barré Syndrome Outcomes Study (IGOS) Researchers Highlights Benefits over Current Standard of Car
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 16'th May 2025
BRISBANE, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastat
Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
08:00am, Monday, 12'th May 2025
FDA Meeting for Tanruprubart (formerly ANX005), the First Potential Targeted Therapy for GBS, Scheduled for Second Quarter 2025 Ahead of Planned BLA Submission
First Oral Presentation by the International Guillain-Barré Syndrome Outcomes Study (IGOS) of the Real-World Evidence (RWE) Results Showing Improved Outcomes with Tanruprubart (formerly ANX005) Compa
